NASDAQ$RNAC
Selecta Biosciences Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Selecta Biosciences reported Q1 2025 earnings with modest collaboration and grant revenue and a continued net loss as clinical development spending remained elevated.
Cartesian Therapeutics generated $1047000 in revenue in Q1 2025 from collaboration and grant funding while reporting a net loss of $17700000 as the company continued investing in the clinical development of Descartes-08 and other autoimmune programs.
- Revenue totaled $1047000 from collaboration and grant funding sources.
- Net loss was $17700000 with EPS of -0.68.
- Operating loss reached $18200000 driven by R&D and administrative spending.
- Cash, cash equivalents and restricted cash totaled $187200000 supporting ongoing clinical trials.
Headline financials
Revenue & EPS history
Selecta Biosciences · Revenue · Quarterly
$1.1M
Forward guidance
Cartesian Therapeutics expects existing capital to support continued clinical development of Descartes-08, including the Phase 3 AURORA trial in myasthenia gravis and expansion into additional autoimmune disease indications.
Tailwinds
- Phase 3 AURORA trial progressing in myasthenia gravis.
- Descartes-08 showed durable responses in prior clinical studies.
- Pipeline expansion planned across multiple autoimmune indications.
- Cash resources support ongoing clinical development programs.
- Additional clinical milestones expected throughout 2025.
Headwinds
- Company remains pre-commercial with limited revenue generation.
- Operating losses continue due to heavy R&D investment.
- Future results depend heavily on clinical trial outcomes.
- Regulatory approval timelines remain uncertain.
- Potential need for additional capital in the long term.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
+0.3%
Avg return
Earnings day
-1.5%
Avg return
5 days after
+0.8%
Avg return
30 days after
36%
14 / 39 earnings
Positive
+43.0%
Q2 2022
Best reaction
-58.1%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.9% | +14.2% | — | |
| Q4 2025 | +31.7% | +7.9% | -10.2% | |
| Q3 2025 | -1.6% | -4.8% | -10.3% | |
| Q2 2025 | -6.6% | +0.4% | -5.7% | |
| Q1 2025 | -5.0% | -4.2% | +5.9% | |
| Q3 2024 | -0.5% | -18.8% | +20.5% | |
| Q2 2024 | -5.9% | -3.8% | -8.7% | |
| Q1 2024 | -5.8% | -7.6% | +57.6% | |
| Q4 2023 | -8.6% | -16.0% | -36.6% | |
| Q3 2023 | +11.7% | +11.7% | -26.6% | |
| Q2 2023 | +3.7% | +7.3% | +4.6% | |
| Q1 2023 | -6.1% | +2.6% | +11.3% | |
| Q4 2022 | -3.1% | -5.0% | -13.1% | |
| Q3 2022 | +0.6% | -4.9% | -18.4% | |
| Q2 2022 | +43.0% | +55.2% | +10.9% | |
| Q1 2022 | +7.4% | -0.6% | +10.2% | |
| Q4 2021 | -5.7% | -16.6% | -32.0% | |
| Q3 2021 | -6.1% | -8.1% | -23.5% | |
| Q2 2021 | +13.1% | +8.9% | +15.4% | |
| Q1 2021 | -0.7% | +3.7% | +65.4% | |
| Q4 2020 | +9.5% | +16.7% | +7.2% | |
| Q3 2020 | -8.2% | -8.2% | -2.7% | |
| Q2 2020 | -4.7% | -3.6% | -21.6% | |
| Q1 2020 | +1.3% | +4.2% | +17.5% | |
| Q4 2019 | -12.3% | -35.6% | -28.5% | |
| Q3 2019 | -8.4% | -9.7% | -1.3% | |
| Q2 2019 | -6.3% | -11.5% | +3.1% | |
| Q1 2019 | -4.8% | -8.4% | -9.6% | |
| Q4 2018 | +37.8% | +21.6% | +22.1% | |
| Q3 2018 | -5.0% | -2.8% | -7.4% | |
| Q2 2018 | +0.9% | -1.5% | +3.8% | |
| Q1 2018 | +1.3% | +10.4% | +16.1% | |
| Q4 2017 | -16.6% | -22.8% | +7.4% | |
| Q3 2017 | -58.1% | -59.9% | -56.0% | |
| Q2 2017 | -1.4% | -7.1% | +3.8% | |
| Q1 2017 | -2.1% | +3.2% | +9.3% | |
| Q4 2016 | +16.1% | +18.9% | +5.7% | |
| Q3 2016 | +27.2% | +17.9% | +20.3% | |
| Q2 2016 | -4.6% | -1.7% | +25.4% | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro